B+
Bull case
30%
Probability
Target price
$178.00
Analysis reference price unavailable
Analysis 2026-09-16 · RankAlpha Sentiment Codex
A
AgilentBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q3 revenue grew 7.3% on a core basis, underlying operating margin exceeded implied guidance, and management raised FY2026 revenue, margin, and EPS expectations. Improving end markets, new-product response, and operating discipline could sustain above-market growth [#SEC-8K-2026-08-26][#PR-EARNINGS-2026-08-31].
Posture
Constructive
Lead driver
Value
What changed
7 setup hits (3d) with net bullish as of 2026-10-24.
What can break
Biocare closing or integration delays could defer expected pathology benefits; completion is not confirmed in the supplied evidence.
Momentum
95
Value
59
Sentiment
47
Setup hits (3d)
7 · Net Bullish
AI TargetsBase $160.00 · Bull $178.00 · Bear $128.00Analysis 2026-09-16; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $182.59
Why
Momentum95 · Δ7d +1.1
Value59 · Δ7d -0.2
Sentiment47 · Δ7d +1.0
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 7 setup hits (3d) with net bullish as of 2026-10-24.
- • Value remains the lead driver in the composite, 7D delta -0.2.
Contradictions & invalidation
- • Biocare closing or integration delays could defer expected pathology benefits; completion is not confirmed in the supplied evidence.
- • Board transition following Koh's retirement warrants monitoring, although the filing states that the decision did not result from a disagreement with Agilent [#8-K-2026-09-08].
- • Some Q3 EPS and margin upside came from tariff refunds, creating a tougher quality-of-earnings comparison.
Catalyst clock
2026-10-31
Q4 execution against raised FY2026 outlook
Lead driver: Value · See fundamentals
Momentum
95
8% active weight
Current posture
7d trendFlat
Δ7d
+1.1
Δ21d
+7.6
Value
59
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-1.0
Sentiment
47
45% active weight
Current posture
7d trendSoftening
Δ7d
+1.0
Δ21d
-11.3
Why this grade
Composite grade B. Momentum 95.3 / Value 59.4 / Sentiment 46.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-16. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$160.00
Analysis reference price unavailable
Analysis 2026-09-16 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$128.00
Analysis reference price unavailable
Analysis 2026-09-16 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$48.79B
Beta
1.30
Shares Out
281.93M
P/E (TTM)
31.3
P/S (TTM)
5.83
P/FCF (TTM)
46.58
Rev YoY
+10.0%
EPS YoY
+58.8%
Gross Margin
+52.8%
Op Margin
+22.9%
Net Debt
$1.75B
Current Ratio
2.10
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data